EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions

Josiane Aparecida Martiniano de Pádua iD, Diego Ribeiro iD, Victor Freire Ferreira de Aguilar, Tuane Ferreira Melo, Lilian Lacerda Bueno, Ana Laura Grossi de Oliveira iD, Ricardo Toshio Fujiwara iD, Kelly Moura Keller iD

Pathogens · 2025

DOI: 10.3390/pathogens14100970 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, 2025. Verfasst von Josiane Aparecida Martiniano de Pádua und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departament of Preventive Veterinary Medicine, Veterinary School, Pampulha Campus, Universidade Federal de Minas Gerais (UFMG), Av. Antônio Carlos 66…. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Dog Diseases, Leishmaniasis Vaccines, Leishmania infantum. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes), Fundação de Amparo à Pesquisa do Estado de Minas Gerais (Fapemig).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Visceral leishmaniasis is a zoonosis commonly caused in Brazil by the parasite Leishmania infantum. This protozoan parasite can infect several species of mammals, with dogs being the main reservoir in urban areas. Several methods are used to prevent the disease, including collars impregnated with 4% deltamethrin to prevent contact between the sandfly and the animal, and vaccines. Vaccines aim to stimulate an immune response that can effectively fight the parasite, with the Th1 immune response being the most desired. There are several research groups around the world dedicated to testing new immunogens against Leishmania spp. and there are currently two commercially available vaccines used to prevent the disease, Neoleish® and Leti-Fend®. Leish-Tec®, a vaccine previously licensed for use in dogs in Brazil, was suspended in May 2023 due to non-compliance in some batches. This also happened with CaniLeish®, which was discontinued by the European Commission in October 2023. These vaccines have different characteristics that influence their use as a public health measure, and therefore the objective of this review is to describe these immunogens, their characteristics, and their use as a collective prevention measure for canine visceral leishmaniasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, VisceralDog DiseasesLeishmaniasis VaccinesLeishmania infantumAnimalsDogsBrazil

Stichwörter der Autor:innen

preventionpublic health measureszoonotic disease

Substanzen

Leishmaniasis Vaccines

Autor:innen und Institutionen

  • Departament of Preventive Veterinary Medicine, Veterinary School, Pampulha Campus, Universidade Federal de Minas Gerais (UFMG), Av. Antônio Carlos 6627, P.O. Box 567, Belo Horizonte 31270-901, Brazil.
  • Department of Veterinary Clinical, Faculty of Veterinary Medicine and Animal Science, Universidade do Estado de São Paulo (UNESP), St. Prof. Doutor Walter Maurício Correa, P.O. Box 560, Botucatu 18618-681, Brazil.
  • Department of Parasitology, Institute of Biological Sciences, Pampulha Campus, Universidade Federal de Minas Gerais (UFMG), Av. Antônio Carlos 6627, P.O. Box 486, Belo Horizonte 31270-901, Brazil.
  • Department of Veterinary Medicine, Faculty of Animal Science and Veterinary Medicine, Universidade Federal de Lavras (UFLA), P.O. Box 3037, Lavras 37200-000, Brazil.
  • Faculty of Medicine, Postgraduate Program in Health Sciences: Tropical Medicine and Infectology, Pampulha Campus, Universidade Federal de Minas Gerais (UFMG), Av. Antônio Carlos 6627, P.O. Box 486, Belo Horizonte 31270-…

ORCID-Profile: Josiane Aparecida Martiniano de Pádua, Diego Ribeiro, Ana Laura Grossi de Oliveira, Ricardo Toshio Fujiwara, Kelly Moura Keller

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes)
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais (Fapemig)
  • Programa de Pós-Graduação em Ciência Animal (PPGCA) da Escola de Veterinária da Universidade Federal de Minas Gerais (UFMG)
  • Universidade Federal de Lavras (UFLA)
  • Universidade do Estado de São Paulo (UNESP)

Zitieren

APA

Martiniano de Pádua, J. A., Ribeiro, D., de Aguilar, V. F. F., Melo, T. F., Bueno, L. L., Grossi de Oliveira, A. L., Fujiwara, R. T., & Keller, K. M. (2025). Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions. Pathogens. https://doi.org/10.3390/pathogens14100970

Vancouver

Martiniano de Pádua JA, Ribeiro D, de Aguilar VFF, Melo TF, Bueno LL, Grossi de Oliveira AL, et al. Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions. Pathogens. 2025. doi:10.3390/pathogens14100970

BibTeX
@article{MartinianodePdua2025,
  author = {Martiniano de Pádua, Josiane Aparecida and Ribeiro, Diego and de Aguilar, Victor Freire Ferreira and Melo, Tuane Ferreira and Bueno, Lilian Lacerda and Grossi de Oliveira, Ana Laura and Fujiwara, Ricardo Toshio and Keller, Kelly Moura},
  title = {Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14100970}
}
Kostenlos starten →